GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50 News

Grifols completed the sale of 20% of Shanghai RAAS Blood Products shares and reached a global strategy cooperation agreement with Haier Group.

With the announcement of today's completed transaction, Grifols and Haier will cooperate through Shanghai RAAS to enhance China's medical care system with synergies. Under the share purchase agreement, Grifols will sell 20% of Shanghai RAAS's shares to Haier Group for RMB 12.5 billion (approximately €1.6 billion). Grifols and Shanghai RAAS will extend their exclusive agency agreement for albumin for the next 10 years, and Shanghai RAAS may choose to extend it to 2044. All of Grifols' revenue will be used to fulfill its deleveraging commitments. Shanghai, June 18, 2024 /PRNewswire/-- Global medical and health companies and leaders.

PR NewswireJun 18 20:02

6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 15 01:20 · Announcements

Grifols 2023 Annual Report on Form 20-F Filed With the SEC

Yahoo FinanceApr 20 04:42